In this article (Cancer Discovery 2015;5:842–9), which was published in the August 2015 issue of Cancer Discovery (1), a mutation is cited erroneously in the Results section under the “Patient 5” subheading. Specifically, the authors incorrectly refer to a MET c.3028+1G>T exon 14 splice site mutation rather than the correct MET p.V1001_F1007del mutation. The affected sentence should instead read, “This demonstrated adenocarcinoma morphologically similar to his initial biopsy and a MET p.V1001_F1007del mutation.” The online version of the article has been corrected and therefore no longer matches the print version. The authors regret this error.
References
1.
Paik
PK
, Drilon
A
, Fan
P-D
, Yu
H
, Rekhtman
N
, Ginsberg
MS
, et al Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing Exon 14 skipping
. Cancer Discov
2015
;5
:842
–9
.©2016 American Association for Cancer Research.
2016
American Association for Cancer Research.